📰 Alligator Bioscience News
Page 2 - Alligator Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alligator Bioscience. Real-time updates on events, politics, business and more.
March 30, 2023
Company Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1Q23 for Solid TumorsSEATTLE, WA / ACCESSWIRE / March 30, 2023
March 5, 2023
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.
February 13, 2023
Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / February 13, 2023 / Alligator Bioscience AB ("Alligator") (Nasdaq
September 19, 2022
Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor typesLUND, SWEDEN and SEATTLE WA / ACCESSWIRE / September 19, 2022 / Alligator
August 2, 2022
Investegate announcements from Evaxion Biotech, Evaxion Biotech A/S Announces Executive Management Changes 
August 1, 2022
/PRNewswire/ -- DelveInsights Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic...
May 21, 2022
Aptevo Therapeutics (NASDAQ:APVO – Get Rating) and Histogen (NASDAQ:HSTO – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings. Profitability This table compares Aptevo Therapeutics and Histogen’s net margins, […]
April 1, 2022
/PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of the patient enrollment for the 600 mg dose cohort from...
March 24, 2022
SEATTLE, WA / ACCESSWIRE / March 24, 2022 /Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary... | March 24, 2022
February 11, 2022
STOCKHOLM, Feb. 11, 2022 /PRNewswire/ -- OPTIMIZE-1 Phase II - On Track and Moving Forward "During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical